Evoke Pharma, Inc. (NASDAQ:EVOK) announced that its healthcare utilization data suggesting reduced healthcare costs for patients on GIMOTI nasal spray versus oral metoclopramide will be presented at the American College of Gastroenterology annual meeting. The data builds upon previous findings demonstrating significant reductions in healthcare resource utilization. The study shows that nasal treatment of diabetic gastroparesis patients not only significantly reduces the number of ER visits and hospitalizations, but also the costs of treatment.